<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02283671</url>
  </required_header>
  <id_info>
    <org_study_id>TolDec-EM-NMO</org_study_id>
    <nct_id>NCT02283671</nct_id>
  </id_info>
  <brief_title>Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara Varea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in human study to assess the tolerability and safety profile of treatment with
      dendritic cell in patients with multiple sclerosis or neuromyelitis optica.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">July 10, 2019</completion_date>
  <primary_completion_date type="Actual">July 10, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with adverse events</measure>
    <time_frame>after 12 weeks of follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite scale</measure>
    <time_frame>after 12 weeks of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Spasticity Scale</measure>
    <time_frame>after 12 weeks of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale</measure>
    <time_frame>after 12 weeks of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF36 Health Status questionnaire</measure>
    <time_frame>after 12 weeks of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol5D</measure>
    <time_frame>after 12 weeks of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in immunological profile</measure>
    <time_frame>after 12 weeks of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of disease outbreaks</measure>
    <time_frame>after 12 weeks of follow up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Neuromyelitis Optica</condition>
  <arm_group>
    <arm_group_label>Tolerogenic dendritic cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Somatic-cell therapy medicines: tolerogenic dendritic cells loaded with myelin peptides.
Patients will receive intravenous administration every two weeks (week 0 , 2 and 4 ) representing a total of three administrations per patient.
The dose escalation will occur as expected in the absence of limiting toxicity in the previous dosage level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tolerogenic Dendritic cells loaded with myelin peptides</intervention_name>
    <description>Somatic-cell therapy medicines application</description>
    <arm_group_label>Tolerogenic dendritic cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with Multiple sclerosis or neuromyelitis optica

          -  diagnosed more than a year before inclusion

          -  Expanded Disability Status Scale between 3.0 and 8.5

          -  all subtypes of multiple sclerosis or Neuromyelitis optica

          -  Multiple Sclerosis patients who have previously been offered therapeutic alternatives
             available in indications and either decline or that after receiving treatment for at
             least 6 months have had an outbreak or an increase of at least 1 point on the Expanded
             Disability Status Scale (EDSS) (non-responders) or who have not tolerated treatment

          -  Patients with Neuromyelitis optica (NMO) in stable immunomodulatory treatment in the
             past 6 months or without treatment because they are not candidates to receive it

        Exclusion Criteria:

          -  Corticosteroid treatment in the last 30 days

          -  Presence of an outbreak in the last month

          -  Inability to perform brain Magnetic resonance imaging (with paramagnetic contrast)

          -  Serious systemic diseases, including Hepatitis B virus, Hepatitis C Virus, and Human
             Immunodeficiency Virus. Uncontrolled hypertension, insulin-dependent diabetes
             mellitus, heart disease or kidney failure or severe respiratory

          -  Personal history of cancer or family history of known hereditary cancer

          -  patient participating in other experimental study in the last 3 months

          -  women childbearing-aged that do not use effective contraceptive methods

          -  pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Villoslada, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut d'Investigacions Biomèdiques August Pi i Sunyer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2014</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Sara Varea</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuromyelitis Optica</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

